Matteo Simonelli

Researcher
Medical Oncology

Senior Clinical and Research Physician at Humanitas Cancer Center – Humanitas Research Hospital

Email matteo.simonelli@hunimed.eu 
Phone +39 02.82244559 or +39 348 5124208
Email humanitas.it/medici/matteo-simonelli or humanitas.it/centri/cancer-center

 

Education and Academic Background

I was born in Milan on October 31, 1979 and I got the high school diploma in classical studies at the Gymnasium Giosuè Carducci of Milan. I graduated at the Medical School of the University of Milan with a vote of 110/110 cum laude in 2004, discussing a thesis entitled “Concentration of circulating DNA and microsatellite alterations in tumor DNA: possible use as prognostic markers in renal cell carcinoma”. My post-graduate education continued with a Medical Oncology Residency degree, achieved in October 2008 with a vote of 70/70 cum laude.
From October 2002 to March 2005 I worked at the Azienda Ospedaliera San Gerardo di Monza, in the medical oncology and radiotherapy Division, as a medical student. From June 2005 to October 2008 I worked at the Istituto Clinico Humanitas, in the Department of Oncology and Hematology, now Humanitas Cancer Center, as clinical and research resident. From November 2008 to date I’m working at Humanitas Cancer Center, since November 2014 as Senior Clinical and Research Physician inside the Clinical Pharmacology Unit and Head of Neuro-oncology.

My academic and teaching career started in 2013 when I became Teaching Tutor for students of the International Medical School, University of Milan. Since 2015 I’ve been Teaching Tutor for students of the Humanitas University and since 2016 Lecturer at Nursing Degree School of Humanitas University.

Scientific and Research Interests

I have a long-standing interest in the field of clinical and translational cancer research and I have been involved in several (more than 50) clinical trials as principal or sub-investigator. Since 2009 I focused my activity in early-phase clinical development of anticancer new drugs (molecular targeted agents; immunotherapeutics agents) inside the clinical Pharmacology Unit, being responsible for the clinical management of the all the phase I studies conducted at the Humanitas Cancer Center.

Since 2014 I became Head of Neuroncology at the Humanitas Cancer Center, being part of the Multidisciplinary Neurongologic Team and conducting clinical trials with new immunotherapeutic agents. I’m principal investigator of several translational projects in the field of Neuroncology and Immuno-Neuroncology aimed to find prognostic or predictive biomarkers for the clinical management of patients with brain tumors.

My principle fields of research interest are:

  • Development of anticancer new drugs
  • Immuno-oncology
  • Neuro-oncology
  • Translational Oncology

Other fields of interest:

  • Rare Thoracic Malignancies (Mesothelioma, Thymoma)
  • Germ-cell tumors
  • High-dose Chemotherapy, Autologous Transplantations

I’m author or co-author of about 40 articles in peer-reviewed journals and ad hoc-reviewer for several international scientific journals. I presented as presenting author (oral presentations) the results of many significant works at the most important International Oncology Meetings, as ASCO (American Society of Clinical Oncology), ESMO (European Association of Medical Oncology), SNO (Society of Neuroncology).

 

Selected publications

  1. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EM, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. – Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036-1041.
  2. Simonelli M, Zucali P, Santoro A, Thomas MB, De Braud FG, Borghaei H, Berlin J, Denlinger CS, Noberasco C, Rimassa L, Kim TY, English PA, Abbattista A, Gallo Stampino C, Carpentieri M, Williams JA. – Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor–like kinase 1 in patients with hepatocellular carcinoma. Ann Oncol. 2016 Sep;27(9):1782-7.
  3. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. A – Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer. 2013 Jan 15;108(1):21-4.
  4. Simonelli M, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A. – Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Eur J Cancer. 2013 Mar;49(5):989-98.
  5. Simonelli M, Rosti G, Banna GL, Pedrazzoli P; on behalf of the Italian Germ cell cancer Group (IGG) and Gruppo Italiano Trapianto Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO). – Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol. 2012 Apr;23(4):815-22.
Why
Humanitas
University?
An Established Institution

An Established Institution
Humanitas is a renowned healthcare institution that has offered Medical Degrees for well over a decade as a partner of the University of Milan.

An International Career

An International Career
Join our international medical community where classes are taught in English by experienced professors and medical doctors from around the world. Your degree will allow you to work as a MD in the EU and abroad.

Clinical Experience

Clinical Experience
Direct clinical experience is supported by a solid tutoring system and starts in your third year, which gives you considerable practical experience.

Innovative and Active Teaching

Innovative and Active Teaching
Humanitas curriculum is enhanced by a wide variety of active learning methods based on a student-centred approach (Problem-Based Learning, Case method, Concept maps, Simulated patients).

Milano and Italy

Milano and Italy
Enjoy the style, culture, gastronomy and entertainment of one of Europe's most exciting cities. Venture further to experience the delights of Italy or use the opportunity to learn Italian.

Advanced Research and Technology

Advanced Research and Technology
Humanitas can count on state-of-the-art technologies and research experience. A new simulation centre of 1000 sm, designed according to the highest technological standards, will be ready for autumn 2017.

Contact Us

Contact
Humanitas University
Via A. Manzoni 113,
Rozzano 20089 Milan, Italy

To receive our updates subscribe here: Newsletter.

How to Reach Us
From Malpensa Airport

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From Linate Airport

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From Central station

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From the city center

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.

From the highway

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.

By public transport

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.